文献速递胸部肿瘤

性别与常见胚系变异影响阿来替尼毒性特征和药代动力学:ALK阳性非小细胞肺癌患者全国队列研究

Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.
PubMed 文献 · J Thorac Oncol · 2024-11-29

这项多中心观察性队列研究纳入215例接受阿来替尼治疗的晚期ALK阳性非小细胞肺癌患者,47%发生严重毒性。女性严重毒性发生率高于男性(56%对34%,p=0.001),阿来替尼谷浓度高35%(p<0.001)。PPAR-α 209G>A纯合携带者3级及以上毒性发生率38%,高于至少携带一个野生型等位基因者的11%(p=0.004)。

要点

  • 女性严重毒性发生率56%对男性34%(p=0.001),谷浓度高35%(p<0.001)。
  • PPAR-α 209G>A纯合携带者3级及以上毒性38%对11%(p=0.004)。
  • 发生严重毒性者谷浓度高18.5%(95%CI 2.9%-36.6%,p=0.019)。

核心结论

  • 女性因阿来替尼暴露更高而遭遇更严重毒性,值得进一步探索。
  • PPAR-α 209G>A显著增加阿来替尼相关毒性,最可能因阿来替尼暴露增加所致。
  • 治疗前检测遗传变异并据此减量,可能为减少阿来替尼相关毒性提供可行方法。

研究设计与样本

  • 多中心观察性队列研究,纳入接受阿来替尼治疗的晚期ALK阳性非小细胞肺癌患者,数据来自五家医院。
  • 共纳入215例患者,分析毒性、药代动力学与ABCB1、CYP3A4、PPAR-α、POR、CYP3A5关键遗传变异的关联。

主要发现

  • 215例患者中47%发生严重毒性。
  • 女性严重毒性发生率56%,男性34%(p=0.001);女性阿来替尼谷浓度较男性高35%(p<0.001)。
  • PPAR-α 209G>A纯合携带者3级及以上毒性发生率38%,至少携带一个野生型等位基因者11%(p=0.004),Bonferroni校正后仍显著。
  • 发生严重毒性者谷浓度较未发生者高18.5%(95%CI 2.9%-36.6%,p=0.019)。

关键数值与推荐

  • 女性严重毒性56%对男性34%(p=0.001)。
  • 女性阿来替尼谷浓度较男性高35%(p<0.001)。
  • PPAR-α 209G>A纯合携带者3级及以上毒性38%对至少一个野生型等位基因者11%(p=0.004)。
  • 严重毒性者谷浓度高18.5%(95%CI 2.9%-36.6%,p=0.019)。

临床怎么用

  • 作者认为,治疗前检测遗传变异并据此减量,可能为减少阿来替尼相关毒性提供可行方法。

局限性

  • 女性患者因阿来替尼暴露更高而遭遇更严重毒性,此点值得进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for ALK-positive (ALK+) NSCLC. Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity. METHODS: In this multicenter observational cohort study in patients with advanced ALK+ NSCLC receiving alectinib treatment, we investigated the association between toxicity, pharmacokinetics, and key genetic variants in ABCB1, CYP3A4, PPAR-α, POR, and CYP3A5. Data on demographics, adverse events, and alectinib trough levels were collected from five hospitals. RESULTS: Among 215 patients, 47% experienced severe toxicity. Women experienced more severe toxicity (female versus male: 56% versus 34%; p = 0.001) and had +35% higher alectinib trough levels (p < 0.001). Homozygous carriers of the PPAR-α 209G>A variant exhibited a higher incidence of grade greater than or equal to 3 toxicity (38%) compared with patients who carried at least one wild-type allele (11%) (p = 0.004). This remained significant after Bonferroni correction. Patients who experienced severe toxicity had +18.5% (95% confidence interval: 2.9%-36.6%; p = 0.019) higher trough levels. CONCLUSIONS: Female patients encounter more severe toxicity due to higher alectinib exposure, which warrants further exploration. PPAR-α 209G>A significantly increased relevant alectinib-induced toxicity, most likely due to an increase in alectinib exposure. Pretreatment testing for genetic variants with a subsequent dose reduction could provide a viable approach to reduce alectinib-related toxicity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Heersche N, Lanser DAC, Muntinghe-Wagenaar MB, et al. Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC. J Thorac Oncol. 2024. PMID: 39617342. doi:10.1016/j.jtho.2024.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。